- 1 Article type: Original Research
- 2 Title: Predicting skin cancer risk from facial images with an explainable artificial intelligence
- 3 (XAI) based approach: a proof-of-concept study
- 4 Authors: X. Liu^{*1,2}, T.E. Sangers^{*3}, T. Nijsten³, M. Kayser⁴, LM. Pardo³, E.B. Wolvius², G.V.
- 5 Roshchupkin^{#1,5}, M. Wakkee^{#3}
- 6
- 7 *These authors contributed equally to this work.
- 8 #These authors contributed equally to this work.
- ¹ Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Center
- 11 Rotterdam, Rotterdam, the Netherlands
- ² Department of Oral & Maxillofacial Surgery, Erasmus MC University Medical Center
- 13 Rotterdam, Rotterdam, the Netherlands
- ³ Department of Dermatology, Erasmus MC Cancer Institute, Erasmus MC University Medical
- 15 Center Rotterdam, Rotterdam, the Netherlands
- ⁴ Department of Genetic Identification, Erasmus MC University Medical Center Rotterdam,
- 17 Rotterdam, the Netherlands
- ⁵ Department of Epidemiology, Erasmus MC University Medical Center Rotterdam, Rotterdam,
- 19 the Netherlands
- 20

21 Corresponding author:

- 22 Marlies Wakkee, MD PhD
- 23 Dr. Molewaterplein 40, 3015 GD Rotterdam
- 24 m.wakkee@erasmusmc.nl
- 25

Funding sources: The Rotterdam Study is funded through unrestricted research grants from
Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the
Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly

29 (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and

- 30 Sports, the European Commission (DG XII), and the Municipality of Rotterdam. G.V.
- Roshchupkin is supported by the ZonMw Veni grant (Veni, 549 1936320).
- 32
- Conflicts of Interest: The authors declare the following financial interests which may be
 considered potential competing interests: The Erasmus MC Department of Dermatology has
 received an unrestricted research grant from SkinVision B.V
- 36

IRB approval status: The Rotterdam Study has been approved by the Erasmus MC Medical
Ethical Committee (MEC-02-1015), and by the Dutch Ministry of Health, Welfare and Sport

- 39 (Population Screening Act, reference 3295110-1021635-PG).
- 40

- 42 43
- 44

46 **Abstract**

45

48 *Background:*

Efficient identification of individuals at high risk of skin cancer is crucial for implementing personalized screening strategies and subsequent care. While Artificial Intelligence holds promising potential for predictive analysis using image data, its application for skin cancer risk prediction utilizing facial images remains unexplored. We present a neural network-based explainable artificial intelligence (XAI) approach for skin cancer risk prediction based on 2D facial images and compare its efficacy to 18 established skin cancer risk factors using data from the Rotterdam Study.

56 *Methods*:

The study employed data from the Rotterdam population-based study in which both skin cancer risk factors and 2D facial images and the occurrence of skin cancer were collected from 2010 to 2018. We conducted a deep-learning survival analysis based on 2D facial images using our developed XAI approach. We subsequently compared these results with survival analysis based on skin cancer risk factors using cox proportional hazard regression.

62 *Findings*:

Among the 2,810 participants (mean Age=68.5±9.3 years, average Follow-up=5.0 years), 228 participants were diagnosed with skin cancer after photo acquisition. Our XAI approach achieved superior predictive accuracy based on 2D facial images (c-index=0.72, SD=0.05), outperforming that of the known risk factors (c-index=0.59, SD=0.03).

67 *Interpretation*:

This proof-of-concept study underscores the high potential of harnessing facial images and a
tailored XAI approach as an easily accessible alternative over known risk factors for identifying
individuals at high risk of skin cancer.

71 Funding:

72 The Rotterdam Study is funded through unrestricted research grants from Erasmus Medical Center

73 and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and

74 Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of

75 Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European

76 Commission (DG XII), and the Municipality of Rotterdam. G.V. Roshchupkin is supported by the

77 ZonMw Veni grant (Veni, 549 1936320).

79 **Research in context**

80 Evidence before this study

81 We searched PubMed for articles published in English between Jan 1, 2000, and Sept 28, 2023,

using the search terms "skin cancer" AND "artificial intelligence" OR "deep learning". Our

search returned more than 1,323 articles. We found no study had explored the feasibility of

84 predicting the risk of developing skin cancer based on facial images that were taken before the

85 first diagnosis of skin cancer. Although there were studies focused on deep learning image

analysis and skin cancer, those are based on skin cancer lesion images. We found current skin

87 cancer risk prediction models are still hampered by dependencies on complex patient data,

88 including genetic information, or rely on self-reported patient data.

89 Added value of this study

90 In this study, we presented a neural network-based explainable artificial intelligence (XAI)

91 approach for skin cancer risk prediction based on 2D facial images. To the best of our

92 knowledge, our study is the first to utilize facial images as predictors in a skin cancer survival

analysis. Our novel image-based approach showed superior performance when juxtaposed with

94 traditional methods that relied on clinical and genetic skin cancer risk factors, as observed within

95 our study population

96 Implications of all the available evidence.

97 This proof-of-concept study underscores the high potential of harnessing facial images and a
98 tailored XAI approach as an easily accessible alternative over known risk factors for identifying
99 individuals at high risk of skin cancer.

101

102 Introduction

Skin cancer, the most common form of cancer in individuals of European ancestry with lighter 103 104 skin tones, presents a significant public health concern. The two most common types of skin cancer, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), together referred to as 105 keratinocyte carcinoma (KC), account for an estimated 6 million¹ new cases each year across the 106 107 globe. BCC, the most prevalent variant, grows slowly, often appearing as nodular, pigmented, or 108 waxy lesions on sun-exposed skin. SCC, though less common than BCC, is more aggressive and usually presents as a scaly or erythematous patch or nodule. Even less common, but far more 109 110 lethal, is malignant melanoma, which causes an estimated 57,000 deaths globally each year.² Due 111 to longer life expectancies and past excessive UV exposure, the number of KC and melanoma cases has surged over recent decades, and this trend is anticipated to continue.² 112

Early diagnosis of skin cancer can mitigate morbidity and mortality by preventing the 113 progression to late-stage disease.³ However, population-wide screening programs have not been 114 proven cost-effective,⁴ or convincingly demonstrated a reduction in skin cancer-related mortality 115 or morbidity. However, personalized screening programs for individuals at high risk of developing 116 skin cancer⁵ are considered as a potentially more feasible strategy to combat the ongoing skin 117 cancer epidemic.⁶ Although accurate stratification of individuals at increased risk of developing 118 119 skin cancer is essential for targeted screening, it remains a challenge to develop tools with sufficient predictive performance that are suitable for wide-scale use. Many existing prediction^{7,8,9} 120 models are hampered by dependencies on complex patient data, including genetic information, or 121 rely on self-reported patient data, thereby making them susceptible to recall bias and social-122 desirability bias.¹⁰ 123

124 Artificial intelligence (AI), specifically convolutional neural networks (CNNs), have 125 demonstrated high accuracy in detecting skin cancer from skin lesion images in recent years.¹¹ Yet, their potential in stratifying individuals based on skin cancer risk remains largely uncharted due to 126 127 the scarcity of longitudinal datasets. One potential direction for such screening strategies involves 128 the use of personal facial images. These images could reveal key risk factors associated with skin 129 cancer, such as age, skin color, and signs of UV damage. Furthermore, capturing facial images requires minimal effort (such as taking a selfie with a smartphone) and is not affected by recall 130 bias thus offering a potentially easily accessible tool for identifying high risk individuals in the 131 132 general population.

Here, we develop a neural network-based explainable artificial intelligence (XAI)^{36,37} approach that predicts skin cancer risk from 2D-facial images and utilize population-based data from the Rotterdam Study (RS) to demonstrate its performance. To assess its effectiveness, we compared the performance of our novel image-based approach with traditional clinical and genetic skin cancer risk factors in RS.

139 Methods

140 Study design and participants

The RS is an ongoing large prospective population-based cohort study in Ommoord, a region in 141 Rotterdam, the Netherlands.¹² Since January 1990, the RS has been enrolling individuals aged 50 142 and over from the general population. Participants undergo comprehensive baseline examinations 143 144 and visit a dedicated study center every 3-4 years. During these visits they also undergo a full-body 145 skin examination (FBSE) performed by a dermatology-trained physician which also focuses on 146 detecting skin (pre-)malignancies and skin cancer. As of 2010, standardized full facial images are 147 taken of participants using a Premier 3dMD face3-plus UHD camera (3dMD Inc., Atlanta, GA, 148 USA).

149

150 Skin cancer and risk factor measurements

151 Skin cancer diagnoses, both prior to and after the facial photo was taken, along with their respective body locations, were collected for all RS participants by linkage to the Dutch nationwide network 152 and registry of histo- and cytopathology (PALGA).¹³ Skin cancer-related risk factors were 153 collected through a combination of home interviews and study center visits. Available skin cancer 154 determinants included sex, age, skin color, hair color, eve color, pigment status (combined 155 variable^{14,15} hair and eye color), number of naevi, baldness in men, body mass index (BMI), 156 157 socioeconomic status, history of living in a sunny country, tendency to develop sunburn, alcohol intake, coffee consumption, smoking, Glogau wrinkle classification, and a genetic risk score (GRS) 158 159 for KC as well as melanoma utilizing single-nucleotide polymorphisms (SNPs) that are significantly associated with these specific types of skin cancer.^{34,35} 160

161

162 **Case definition**

Events were defined as participants, who received their first diagnosis of skin cancer (BCC, SCC) 163 or melanoma) after the date of the facial images being taken. To ensure the exclusion of participants 164 165 who already had a skin cancer diagnosis at the time of the photograph (i.e., *left-censored* samples), individuals with a confirmed histopathological skin cancer diagnosis prior to their photograph or 166 167 within 30 days after the FBSE were excluded from the study. Follow-up of all participants ended at the time of death, or the date of censoring on July 1st, 2018, whichever came first. Death was 168 169 ascertained through linking with the municipal register. *Right-censored* samples were defined as participants, who had not received a diagnosis of skin cancer by the date of censoring (July 1st, 170 2018), or who died before the date of censoring. 171

172

173 Facial image acquisition and preprocessing

174 Facial images of the RS participants were taken using a 3dMDface system (3dMD Inc., Atlanta, GA, USA) photogrammetric device by medical doctors, who were specifically trained in operating 175 the device. The system comprised a central modular camera unit, flanked by two additional side 176 units, and underwent daily calibration. Image acquisition took place in a designated 3D imaging 177 178 room with consistent ambient lighting. An adjustable chair was used in a fixed position, to ensure 179 a standard level of height and fixed distance between subjects and the camera system. Participants 180 were requested to remove glasses and to wear a hair band to prevent hair from obscuring the 181 forehead or ears. During the image capture process, participants faced the central modular camera unit maintaining a neutral facial expression with their eyes open. Frontal 2D facial images were 182 automatically derived from the 3dMD software. 183

For the detection of facial landmarks, we utilized Dlib,¹⁶ a facial image processing library. The detected facial landmarks were subsequently employed to crop and align the facial regions, as illustrated in Figure S8. To exclude the neck or shoulder regions from the images, those areas were masked as black pixels. Additionally, histogram equalization was applied to enhance the visual quality of each facial image as well as to mitigate potential lighting variations. The final resolution employed for our analysis was set to 224x224 pixels.

190

191 Deep learning analysis

192 AI-based endophenotypes derived from facial images

An autoencoder is an artificial neural network architecture employed for learning compressed representations of input data in a self-supervised manner, meaning that it does not require patientspecific information during the training process. The autoencoder consists of an encoder and a decoder, which collectively enable non-linear feature mapping. The encoder is responsible for compressing high-dimensional facial images into low-dimensional latent features, while the decoder reconstructs facial images from these latent features.

199 Z = Encode(F)

200 F'=Decode(Z)

where $Z = [Z_0, Z_1, ..., Z_N]$ denotes the N latent features, Encode() and Decode() functions correspond to the down-sampling and up-sampling processes F denotes the input 2D facial image, while F' represents the reconstructed 2D facial image.

For our analysis, we used a deep convolutional autoencoder¹⁷ (detailed architecture in Figure S3c) consisting of four encoder layers and four decoder layers to derive low-dimensional representations, which we further defined as facial endophenotypes. To make the trade-off between reconstruction error and dimensional complexity, we conducted experiments with varying numbers of

endophenotypes. The optimum number was found to be 200. The derived facial endophenotypeswere further used as predictors in the survival analysis.

210

211 *Explainable AI (XAI) techniques*

By selectively decoding a subset of endophenotype(s), we are able to generate a sequence of facial images showing changes in facial features corresponding to the changes of selected endophenotype(s). Implementation details about the selectively decoding can be found in Figure S5a (in supplementary).

216

217 Cox proportional hazard regression (CPH) analysis

We performed a survival analysis employing cox proportional hazard regression (CPH),¹⁸ to predict the risk of participants developing skin cancer over time. Predictors included either the 18 risk factors or the 200 facial endophenotypes. Additionally, time-to-event (TTE) was included as an essential predictor in the model training. For events, TTE was calculated as the interval between the date of the first diagnosis of skin cancer and the date when the facial image was taken; In the case of right-censored samples, TTE was calculated as the interval between the date of censoring (or death) and the date when a facial image was taken.

225

226 Deep cox proportional hazards regression (DCPH) analysis

A deep cox proportional hazard regression (DCPH) model is an extension of the linear cox proportional hazards (CPH) model. Compared to DPH, DCPH enables non-linear modeling of the predictors, and thus it is able to model more complex relationships between predictors and the

risk.¹⁹ The parameters of the DCPH model are optimized by minimizing the following log-partial
likelihood cost function which is widely used in survival analysis models:^{20,21,22}

232
$$Loss = -\sum_{i \in E} (h(x_i) - \ln \sum_{j \in R} e^{h(x_j)})$$

where E represents the set of events and R denotes the set of right-censored samples, and the TTE for individual j is greater than the TTE for individual i, x_i and x_j represent the predictors for individuals i and j, and h(x) and $h(x_i)$ represent the network predictions for individuals i and j.

The DCPH model consisted of two fully connected layers and one neuron in the output layer.

237 Detailed architectures of the DCPH model can be found in Supplementary Figure S3b.

238

239 Deep Convolutional cox proportional hazards regression analysis (DCCPH)

Integrating 2D convolutional neural networks²³ with the cost function of DCPH, we can utilize the entire facial image as input and directly compute a skin cancer risk score for each participant. This integrated model was referred to as the deep convolutional cox proportional hazard (DCCPH) model, which consisted of four convolutional layers, two fully connected layers and one neuron in the output layer. Detailed architectures of the DCCPH model can be found in Supplementary Figure S3c.

246

247 Survival analysis and experiment settings

In all experiments of the survival analysis, left-censored samples (i.e., participants diagnosed with skin cancer prior to the facial image being taken) were excluded. We utilized three models in the survival analysis: CPH, DCPH, and DCCPH. For both the CPH and DCPH models, we explored three types of predictors: 1) age alone, 2) 18 known risk factors, and 3) facial endophenotypes. In

the DCCPH model, we employed 2D facial images without extracting facial endophenotypes aspredictors.

All the three models estimate the risk over time, but we only provide the risk score at a single time point, which is at the end of the study. To evaluate the predictive performance of the models, we calculated the concordance-index (c-index) using the following equation:

257
$$C = \frac{\sum_{i \neq j} 1(r_i < r_j) 1(T_i > T_j) \delta_j}{\sum_{i \neq j} 1(T_i > T_j) \delta_j}$$

where δ_j is a variable that is assigned a value of 1, if individual j is an event and 0 if individual j is a right-censored sample, T is the TTE for an individual and r is the risk score for an individual.

A c-index of 0.5 indicates a random prediction, while a c-index of 1 indicates a perfect prediction. In all prediction experiments, we employed a consistent practice of splitting the samples into a training set and a test set, with an 80:20% ratio. We repeated this split 20 times with random permutations and calculated the mean and standard deviation of the c-index.

We performed an additional analysis where we stratified the right-censored samples into different 264 subgroups based on their follow-up years. It is important to note that patient information in this 265 study was not updated beyond July 1st, 2018. Consequently, some right-censored samples had a 266 relatively short follow-up period and may have been diagnosed with skin cancer shortly after that 267 268 date. These right-censored samples with a shorter follow-up time could be deemed less reliable compared to those with longer follow-up periods. In consequence, including right-censored 269 270 samples with short follow-up years in the analysis could potentially impact the prediction model 271 negatively. Therefore, we stratified the right-censored samples into 5 subgroups based on the 272 follow-up years, while ensuring age matching among the subgroups. The subgroups were defined as follows: 1) > 2 follow-up years (N=1139); 2) > 3 follow-up years (N=1129); 3) > 4 follow-up 273 274 years (N=840); 4) > 5 follow-up years (N=548); 5) > 6 follow-up years (N=535), The event group

275	consisted of participants who were diagnosed with skin cancer at any location on the body (N=228).
276	Subsequently, we performed separate survival analysis for each sub-group in this additional
277	analysis.
278	
279	Ethical considerations
280	The Rotterdam Study has been approved by the Erasmus MC Medical Ethical Committee (MEC-
281	02-1015), and by the Dutch Ministry of Health, Welfare and Sport (Population Screening Act,
282	reference 3295110-1021635-PG). Written informed consent was obtained from all participants.
283	
284	
285	

286 **Results**

288

287 Study population and risk factors

We included a total of 3.371 participants from the RS cohort, who had a 2D-facial image and 289 290 underwent assessment for skin cancer risk factors. Among them, 23.4% (n=789) were diagnosed 291 with skin cancer, of which 71.1% (n=561, *left-censored* participants) were diagnosed prior to the 292 facial image being taken, and 28.9% were diagnosed afterwards (n=228, *events*). Figure S7 shows the histogram distribution of time-to-event (TTE) of these 228 events, with an average TTE of 971 293 294 days (SD 678 days). Among these 228 events, 163 had a BCC, 68 had an SCC and 11 had a 295 melanoma. Left-censored participants were excluded from the survival analysis. Table 1 shows the distribution of the 18 potential skin cancer risk factors among the study population (N=2.810), of 296 297 which the median age was 67.1 years (IQR 14.1 years) and 57.4% were women. We examined the association between known skin cancer risk factors and the facial endophenotypes we derived from 298 299 the facial images (Figure S4), and visually represented the identified associations on the face (Figure S5) via XAI techniques. 300

301

302	Table 1: Baseline	characteristics	of the RS	study population.

	Participants, who did not develop skin cancer (Right- censored samples) N=2582	Participants, who developed skin cancer after facial image taken (Events) N=228
Age at FBSE in years, median (IQR)	66.8 (14.2)	70.6 (12.0)
Sex -Women (%) -Men (%)	1484 (57.5%) 1098 (42.5%)	129 (56.6%) 99 (43.4%)
BMI mean (SD)	27.67 (4.39)	27.75 (3.97)

Skin color -Olive color-light brown (%) - White (%) - Pale (%)	373 (14.4%) 1908 (73.9%) 301 (11.7%)	23 (10.1%) 183 (80.3%) 22 (9.6%)
Hair color when young -Black (%) -Brown/dark blonde (%) -Light blonde (%) -Red (%)	155 (6.0%) 1844 (71.4%) 505 (19.6%) 78 (3.0%)	9 (3.9%) 166 (72.8) 40 (17.5%) 13 (5.7%)
Eye color -Brown (%) -Intermediate (%) -Blue (%)	596 (23.1%) 211 (8.2%) 1775 (68.7%)	48 (21.1%) 21 (9.2%) 159 (69.7%)
Pigment status (combined variable ^{14,15} hair and eye color) -Light (%) -Intermediate (%) -Dark (%)	538 (20.8%) 1467 (56.8%) 577 (22.3%)	49 (21.5%) 134 (58.8%) 45 (19.7%)
Baldness -No/almost no (%) -Mild (%) -Severe (%)	1923 (74.5%) 346 (13.4%) 313 (12.1%)	157 (68.9%) 31 (13.6%) 40 (17.5%)
Number of naevi - >=100 (%) - 50-99 (%) - 25~49 (%) - <25 (%)	49 (1.9%) 141 (5.5%) 371 (14.4%) 2021 (78.3)	4 (1.8%) 9 (3.9%) 30 (13.2%) 185 (81.1%)
Glogau wrinkle classification - 1 and 2 (%) - 3 (%) - 4 (%)	207 (8.0%) 2027 (78.5%) 348 (13.5%)	12 (5.3%) 175 (76.8%) 41 (18.0%)
Socioeconomic status -high (%) -medium (%) -low (%)	755 (29.2%) 1505 (58.3%) 322 (12.5%)	56 (24.6%) 134 (58.8%) 38 (16.7%)
History of living in a sunny country -Yes (%) -No (%)	150 (5.8%) 2432 (94.8%)	17 (7.5%) 211 (93.5%)

Tendency to develop sunburn -Yes (%) -No (%)	866 (33.5%) 1716 (66.5%)	86 (37.7%) 142 (62.3%)
Alcohol intake g/day mean (SD)	7.95 (8.57)	8.08 (9.42)
Smoking -Ever (%) -Never (%)	1756 (68.0%) 826 (32.0%)	157 (68.9%) 71 (31.1%)
Coffee consumption (cups/day) mean (SD)	3.03 (1.83)	2.99 (1.81)
GRS_KC median (SD)	1.03 (0.25)	1.06 (0.27)
GRS_MM, median (SD)	7.03 (0.47)	7.06 (0.46)

304 Right-censored samples: Never had skin cancer before the end of the study;

305 Events: Diagnosed with skin cancer at least 30 days after the facial photo was taken;

306 FBSE: Full-body skin examination;

307 GRS_KC: Polygenetic risk score for KC;

308 GRS_MM: Polygenetic risk score for melanoma

309 Risk factors were imputed. Table S1 shows the characteristics of non-imputed risk factors.

310

311 Skin cancer risk prediction in survival analysis

312

Table 2 shows the c-index values for different prediction models using various predictors as input.

In the risk factor analysis, the age-only analysis yielded a c-index of about 0.55, which increased

to 0.59 when all other known risk factors were included. However, the analysis of facial

endophenotypes resulted in higher c-index values of 0.72, which remained similar at 0.71 when

using the facial images without extracting the facial endophenotypes. Comparing the prediction

models, the CPH showed better performance when using risk factors as input, while the DCPH

319 was more effective when employing facial endophenotypes as input.

- In our main analysis, we focused on skin cancer occurring at any location on the body. We further 320
- stratified the event group into two subgroups: skin cancer on the face and skin cancer on other 321
- 322 parts of the body excluding the face. Interestingly, we observed similar patterns and trends in the
- analysis across different stratifications based on the location of skin cancer. 323
- 324
- 325 Table 2: C-index (mean/SD) of skin cancer risk prediction in survival analysis.

Method (predictors)	Skin cancer on any location of body N = 228	Skin cancer on face N = 136	Skin cancer on other parts of the body except face N=113
CPH age only	0.550/0.048	0.554/0.036	0.543/0.051
CPH 18 known risk factors	0.589/0.034	0.586/0.047	0.595/0.060
DCPH 18 known risk factors	0.572/0.044	0.520/0.067	0.532/0.069
CPH facial endophenotypes	0.685/0.033	0.693/0.037	0.674/0.054
DCPH facial endophenotypes	0.721/0.045	0.732/0.058	0.718/0.049
DCPH facial endophenotypes + age	0.723/0.039	0.738/0.060	0.721/0.062
DCCPH 2D facial image without extracted endophenotypes	0.713/0.041	0.721/0.051	0.703/0.049

326 CPH: Cox proportional hazard regression

DCPH: Deep Cox proportional hazard regression 327

DCCPH: Deep convolutional cox proportional hazards regression 328

Only Right-censored samples (N = 535) with > 6 follow-years were included. 329

Results were based on imputed risk factors. Table S2 shows the results based on non-imputed risk factors. 330 331

332 Facial endophenotypes association with known risk factors

- Figure 1 shows the associations between traditional skin cancer risk factors and statistically 333
- 334 significant facial endophenotypes identified in the survival analysis (CPH facial endophenotypes)
- in Table 2. Combining the effects of 12 statistically significant facial endophenotypes, several key 335

patterns emerged. Strong associations of facial endophenotypes were observed with age (positive),
Glogau wrinkle classification (positive), history of living in a sunny country (positive), BMI
(negative), and hair color and pigment status (higher risk in lighter color). Weaker associations
were found with sex (higher risk in males), tendency to develop sunburn (negative) and skin color
(higher risk with lighter skin color). No significant associations were detected with alcohol
consumption, coffee consumption, smoking, eye color, social economic status, number of naevi,
baldness and genetic risk score.





344

Figure 1. Statistically significant facial endophenotypes in survival analysis are associated with known risk factors,

in the analysis of skin cancer on any location of the body. The x-axis represents the different risk factors, while the

y-axis represents the index of facial endophenotypes that exhibited statistical significance in the survival analysis.
The "sum" row represents the summation of each row. The values of associations are normalized from -1 to 1 for

each column, where red indicates a positive association, indicating a higher risk of skin cancer associated with

- 350 higher values of the corresponding risk factor, such as age.
- 351
- 352

353 Explainable AI (XAI)

In order to gain insights into the facial features contributing to skin cancer prediction, we 354 selectively decoded the statistically significant facial endophenotypes identified in the survival 355 analysis (CPH facial endophenotypes) and generated a sequence of facial images representing low 356 to high risk of skin cancer via XAI techniques (implementation details in Figure S5a). Figure 2 357 presents synthesized facial images that the prediction model considered as having low to high risk 358 of skin cancer, stratified based on whether the cancer occurred on the face, on other body parts 359 360 excluding the face, or anywhere on the body including the face. The result indicates that factors such as a lower BMI or increased facial erythema might be linked to a higher risk. Notably, 361 participants in the sub-group of skin cancer occurring outside the face had never been diagnosed 362 363 with skin cancer on the face before the date of censoring.

364

Skin cancer on any location



365 366

Figure 2: Reconstruction of faces representing lower to higher risk for developing skin cancer on the face, and other
body locations excluding the face, as well as anywhere on the body including the face. The synthetic faces shown in
the figure were reconstructed via selectively decoding statistically significant facial endophenotypes in the survival
analysis (CPH facial endophenotypes) in Table 2.

372 In-depth analysis of TTE in survival analysis

373

The relationship between the skin cancer prediction score and TTE of events during the test stage 374 of the survival analysis (CPH and DCPH facial endophenotypes) is illustrated in Figure 3. Notably, 375 the TTE information of each participant was not included into the model as a predictor in the test 376 stage. The plot reveals that events with a higher prediction score, indicating a higher risk of skin 377 cancer, tend to have a shorter TTE. A shorter TTE implies that participants were diagnosed with 378 skin cancer earlier after the facial images were taken, suggesting that their faces may have 379 380 exhibited early signs of skin cancer at the time the photo was made. The CPH and DCPH models effectively identified these participants, assigning them to overall higher risk scores compared to 381 subjects with a longer TTE. This effect, although to a lesser extent, was also observed for 382 383 participants with skin cancer on other parts of the body excluding the face (Figure S9).



Figure 3: Relationship between risk prediction score and time to event (TTE) for N=44 events in the test set. a)
Analysis of (CPH facial endophenotypes) and b) Analysis of (DCPH facial endophenotypes) for skin cancer at any
location on the body. The X-axis represents the TTE in days, while the Y-axis represents the prediction risk score
normalized to a range of 0 to 1. A higher predicted score indicates a higher risk of skin cancer.

390

384 385

Figure 4 shows the survival analysis results with the stratification of right-censored samples based on their follow-up years. Age was matched between the event group and right-censored subgroups, so the c-index curve of (CPH age) served as a baseline. It is evident that compared to (CPH age), the results of (CPH 18 known risk factors), (CPH facial endophenotypes) and (DCPH facial endophenotypes) showed a trend of increasing c-index in subgroups with longer follow-up years.



397

398 Figure 4: Stratification of right-censored samples based on follow-up years. The solid line represents the mean

result, while the transparent surrounding area denotes the standard deviation. (CPH 18 known risk factors): Results
 obtained from a CPH model using risk factors as predictors. (DCPH facial endophenotypes): Results obtained from a

401 DCPH model using facial endophenotypes as predictors.

403 **Discussion**

Our research underscores the promise of using facial endophenotypes, extracted from 2D facial 404 405 images through AI techniques, as indicators for developing skin cancer in the future. We demonstrate that the innovative use of facial image-based predictions outperformed traditional 406 407 methods relying on many known risk factors, which are normally identified based on complex 408 patient information, including extensive questionnaires, genetic data, and clinical parameters 409 identified during physical skin cancer screening, such as nevi count, AK, or wrinkles. Our analysis 410 confirms the robust relationship between these facial endophenotypes and established skin cancer risk determinants. We found a notable correlation between the most predictive facial 411 412 endophenotypes and certain recognized risk factors for skin cancer.

Facial endophenotypes provide a rapid, user-friendly and explainable AI-based alternative to existing risk factors, particularly when comprehensive patient information is difficult to collect on a large scale. Furthermore, these endophenotypes might offer a more consistent prediction of skin cancer risk than relying on questionnaire data, sidestepping potential recall biases. To the best of our knowledge, our study is the first to utilize facial images and facial endophenotypes derived from these images as predictors in a skin cancer survival analysis.

419 *Relevance to existing literature*

Previous modeling studies reported targeted skin cancer screening of high-risk populations to be a cost-effective²⁴ population-based intervention to reduce skin cancer related morbidity and mortality. However, the characteristics of individuals that are considered 'high risk' vary across studies.²⁵ Our findings provide promises that facial endophenotypes can help in narrowing the scope of high-risk individuals to optimize cost-effectiveness and improve the feasibility of targeted screening programs.

426 The current literature on skin cancer risk prediction encompasses a range of prediction models with varying levels of accuracy. While some models have demonstrated promising results 427 using relatively simpler factors, such as the number of actinic keratosis and coffee consumption 428 (c-index 0.6),²⁶ others have incorporated more extensive patient information to achieve improved 429 accuracy. Notably, a model focused on melanoma risk achieved c-index values of 0.72 for any 430 melanoma and 0.69 for invasive melanoma by incorporating seven relevant predictors.²⁷ In our 431 432 study, utilizing facial endophenotypes outperformed the predictive accuracy based on known risk factors alone, yielding a c-index of 0.73, which surpasses the performance of many published 433 434 models. Recent research has broadened its scope, incorporating up to 32 genetic and non-genetic risk factors to remarkably enhance the accuracy of predicting future skin cancer development.⁴⁰ 435 436 Nonetheless, it's vital to acknowledge that making direct comparisons between our study and prior 437 investigations presents challenges due to variations in the populations, research methodologies employed, and, notably, the divergent primary outcomes assessed in these studies. 438

Our study also revealed associations between several facial endophenotypes and known risk factors for skin cancer such as age, sex, BMI, Glogau wrinkle score, hair and skin color, history of living in a sunny country, tendency to develop sunburn, and pigment status. Age is a wellknown risk factor for skin cancer,^{28,29,30} with many existing prediction models relying heavily on it. Similarly, our prediction model leaned heavily on age as a discriminative variable when our analysis was restricted to known skin cancer risk factors.

Interestingly, we were also able to corroborate previous studies that found an inverse
correlation between BMI and KC, meaning a higher BMI appears to reduce the risk of KC).^{31,32}
However, other studies focusing on melanoma observed a positive correlation with BMI.³³ Given

the substantial proportion of KC patients within our study cohort relative to melanoma patients,this has likely skewed our results towards an inverse correlation.

450 Furthermore, we found several facial endophenotypes associated with sex to be predictive of skin cancer. Men are known to have a higher risk of developing skin cancer than women, 451 particularly in the case of melanoma. This disparity can be attributed to a mix of genetic and 452 453 behavioral factors, including men's tendency to have more sun exposure and less protection from ultraviolet (UV) radiation due to occupational and recreational activities and less care to protect 454 455 from UV with cosmetics. Moreover, individuals with lighter skin tones and hair colors are more 456 susceptible to skin cancer, including both KC and melanoma, due to their decreased melanin levels, which leaves them less protected against UV radiation. Residing in a sunny country also increases 457 skin cancer risk due to higher cumulative exposure to UV radiation. Surprisingly, our study 458 459 identified an inverse relationship between the tendency to develop sunburn and the risk of skin 460 cancer. This counterintuitive finding could be attributed to a chance finding as this association was 461 relatively weak. Furthermore, we were unable to correlate other known skin cancer risk factors to facial endophenotypes, such as coffee consumption and the number of nevi. This outcome is 462 anticipated, as these risk factors would be less likely to be reflected in facial images. 463

464 *Strengths and limitations*

Strengths of this study include the use of extensive population-based data from the Rotterdam Study, with over 7 years of follow-up data. Additionally, the inclusion of nationwide data on skin cancer diagnosis from the Dutch National Histopathology Registry reduces the risk of having missed skin cancer diagnoses in the studied individuals during the study follow-up period. Nevertheless, the results of our study should be understood in the context of several limitations. First, given the proof-of-concept design of our study and, as far as we are aware of, no publicly

available datasets worldwide containing both facial images and follow-up skin cancer data, we 471 472 were unable to externally validate our algorithm using an independent dataset. Second, facial 473 images in the Rotterdam Study were collected using a highly standardized method with a dedicated camera setup, which could result in suboptimal performance when other, out-of-distribution facial 474 photos taken under different capturing conditions (e.g., selfies taken with a front-facing 475 476 smartphone camera) are used in our AI model, which can be tested in future studies. Also, a portion 477 of right-censored samples included in our analysis had a short follow-up period, meaning they 478 might have developed skin cancer shortly after this study's follow-up period ended, potentially 479 impacting the prediction model negatively. Furthermore, as Rotterdam Study participants are of Dutch European ancestry and thus in majority having fair skin colour, the training and testing 480 dataset of this study was unbalanced in terms of skin colour diversity, which may make our model 481 less reliable when used for individuals with darker skin tones. Moreover, the study cohort is 482 483 relatively old (mean age around 68) affecting the generalizability of the findings, suggesting that 484 the impact of age may be even more dominant in the general population with a different age distribution, which should be tested in the future. Finally, we implemented an XAI approach in an 485 attempt to shed light on the risk predictions made by our AI system. We did this by generating 486 487 synthetic facial images associated with higher or lower risks of developing skin cancer. This method provides some insights, indicating that factors such as a lower BMI or increased facial 488 489 erythema might be linked to a higher risk. But the inherent complexity of deep learning algorithms 490 restricts our ability to fully understand the specific elements that boost the model's accuracy.

491 Conclusion

492 In conclusion, our research underscores the high potential of using facial images in deep-learning

models for targeted skin cancer screening. The novel AI-driven approach we introduce here
eliminates the need for collecting information via lengthy questionnaires, DNA collection,
genotyping, or in-person evaluations. However, before it can be integrated into personalized
screening programs, further validation within diverse population samples and less standardized
setting is needed.

498

499 Acknowledgements

The Rotterdam Study is funded by the Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly, the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (Directorate-General XII), and the Municipality of Rotterdam. G.V. Roshchupkin is supported by the ZonMw Veni grant (Veni, 549 1936320). The authors are grateful to the study participants, the staff from the Rotterdam Study, and the participating general practitioners and pharmacists.

507 Data sharing

De-identified data used in this study is currently not publicly available. Researchers interested in
data access should contact the corresponding author. Data requests will need to undergo ethical
and legal approval by the relevant institutions.

511 Author contributions

- 512 All authors made significant contributions to this scientific work and approved the final version
- of the manuscript. X.L. and T.E. were involved in the conception and design of the study,
- conducted the method development and experiments, and wrote the article. M.W and G.V.R.
- were involved in the conception and design of the study, supervised the method development and
- design of experiments, and co-wrote the article. T.N, M.K, LM.P. and E.B.W. were involved in
- the conception and design of the study, reviewed the manuscript, and provided consultation
- regarding the analysis and interpretation of the data. X.L. and T.E. have directly accessed and
- 519 verified the underlying data reported in the manuscript.

520 Conflicts of interest

- 521 The authors declare the following financial interests which may be considered potential
- 522 competing interests: The Erasmus MC Department of Dermatology has received an unrestricted
- 523 research grant from SkinVision B.V.

524

References 525

- 526 1. Zhang, W, Zeng, W, Jiang, A, et al. Global, regional and national incidence, mortality and
- disability-adjusted life-years of skin cancers and trend analysis from 1990 to 2019: An analysis 527
- of the Global Burden of Disease Study 2019. Cancer Med. 2021; 10: 4905–4922. 528
- https://doi.org/10.1002/cam4.4046 529
- 530 2. Arnold M, Singh D, Laversanne M, et al. Global Burden of Cutaneous Melanoma in 2020 and
- Projections to 2040. JAMA Dermatol. 2022;158(5):495-503. 531
- 532 doi:10.1001/jamadermatol.2022.0160
- 533 3. Weinstock MA. Early Detection of Melanoma. JAMA. 2000;284(7):886–889.
- 534 doi:10.1001/jama.284.7.886
- 4. Henrikson NB, Ivlev I, Blasi PR, Nguyen MB, Senger CA, Perdue LA, Lin JS. Skin Cancer 535
- Screening: Updated Evidence Report and Systematic Review for the US Preventive Services 536 537 Task Force. JAMA. 2023 Apr 18;329(15):1296-1307. doi: 10.1001/jama.2023.3262. PMID:
- 37071090. 538
- 5. Wernli KJ, Henrikson NB, Morrison CC, Nguyen M, Pocobelli G, Blasi PR. Screening for 539
- Skin Cancer in Adults: Updated Evidence Report and Systematic Review for the US Preventive 540 Services Task Force. JAMA. 2016 Jul 26;316(4):436-47. doi: 10.1001/jama.2016.5415. PMID: 541
- 27458949.
- 542
- 6. Asgari MM, Crane LA. Skin Cancer Screening: The Importance of Identifying High-risk 543
- Subgroups and the Need for US-Based Population Research. JAMA. 2023;329(15):1259–1260. 544 doi:10.1001/jama.2023.3259 545
- 7. Fontanillas, P., Alipanahi, B., Furlotte, N.A. et al. Disease risk scores for skin cancers. Nat 546 Commun 12, 160 (2021). https://doi.org/10.1038/s41467-020-20246-5 547
- 8. Cust AE, Badcock C, Smith J, Thomas NE, Havdu LE, Armstrong BK, Law MH, Thompson 548
- 549 JF, Kanetsky PA, Begg CB, Shi Y, Kricker A, Orlow I, Sharma A, Yoo S, Leong SF, Berwick
- M, Ollila DW, Lo S. A risk prediction model for the development of subsequent primary 550
- melanoma in a population-based cohort. Br J Dermatol. 2020 May;182(5):1148-1157. doi: 551
- 10.1111/bjd.18524. Epub 2019 Nov 27. PMID: 31520533; PMCID: PMC7069770. 552
- 553 9. Wang H, Wang Y, Liang C, Li Y. Assessment of Deep Learning Using Nonimaging
- Information and Sequential Medical Records to Develop a Prediction Model for Nonmelanoma 554
- 555 Skin Cancer. JAMA Dermatol. 2019;155(11):1277-1283. doi:10.1001/jamadermatol.2019.2335

10. Fontanillas P, Alipanahi B, Furlotte NA, Johnson M, Wilson CH; 23andMe Research Team;
Pitts SJ, Gentleman R, Auton A. Disease risk scores for skin cancers. Nat Commun. 2021 Jan
8;12(1):160. doi: 10.1038/s41467-020-20246-5. PMID: 33420020; PMCID: PMC7794415.

11. Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, Thrun S. Dermatologist-level
classification of skin cancer with deep neural networks. Nature. 2017 Feb 2;542(7639):115-118.
doi: 10.1038/nature21056. Epub 2017 Jan 25. Erratum in: Nature. 2017 Jun 28;546(7660):686.
PMID: 28117445; PMCID: PMC8382232.

12. Ikram MA, Brusselle G, Ghanbari M, Goedegebure A, Ikram MK, Kavousi M, Kieboom
BCT, Klaver CCW, de Knegt RJ, Luik AI, Nijsten TEC, Peeters RP, van Rooij FJA, Stricker

565 BH, Uitterlinden AG, Vernooij MW, Voortman T. Objectives, design and main findings until

566 2020 from the Rotterdam Study. Eur J Epidemiol. 2020 May;35(5):483-517. doi:

567 10.1007/s10654-020-00640-5. Epub 2020 May 4. PMID: 32367290; PMCID: PMC7250962.

13. Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH, Meijer

569 GA. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the

570 nationwide histopathology and cytopathology data network and archive. Cell Oncol.

571 2007;29(1):19-24. doi: 10.1155/2007/971816. PMID: 17429138; PMCID: PMC4618410.

572 14. Tokez S, Alblas M, Nijsten T, Pardo LM, Wakkee M. Predicting keratinocyte carcinoma in

573 patients with actinic keratosis: development and internal validation of a multivariable risk-

574 prediction model. Br J Dermatol. 2020 Sep;183(3):495-502. doi: 10.1111/bjd.18810. Epub 2020

575 Feb 26. PMID: 31856292; PMCID: PMC7496285.

576 15. Verkouteren JAC, Smedinga H, Steyerberg EW, Hofman A, Nijsten T. Predicting the Risk of
a Second Basal Cell Carcinoma. J Invest Dermatol. 2015 Nov;135(11):2649-2656. doi:
10.1038/jid.2015.244. Epub 2015 Mar 3. PMID: 26121210.

579 16. Davis E. King. Dlib-ml: A Machine Learning Toolkit. Journal of Machine Learning Research
580 10, pp. 1755-1758, 2009

581 17. X. Hou, L. Shen, K. Sun and G. Qiu,""Deep Feature Consistent Variational Autoencoder"

2017 IEEE Winter Conference on Applications of Computer Vision (WACV), Santa Rosa, CA,
USA, 2017, pp. 1133-1141, doi: 10.1109/WACV.2017.131.

18. Harrell, F.E. (2015). Cox Proportional Hazards Regression Model. In: Regression Modeling
Strategies. Springer Series in Statistics. Springer, Cham. <u>https://doi.org/10.1007/978-3-319-</u>
<u>19425-7_20</u>

587 19. Katzman, J.L., Shaham, U., Cloninger, A. et al. DeepSurv: personalized treatment

recommender system using a Cox proportional hazards deep neural network. BMC Med Res

589 Methodol 18, 24 (2018). <u>https://doi.org/10.1186/s12874-018-0482-1</u>

590 20. A. Cheerla and O. Gevaert. Deep learning with multimodal representation for pancancer 591 prognosis prediction. Bioinformatics, 35(14):i446–i454, 2019.

- 592 21. P. Mobadersany, S. Yousefi, M. Amgad, D. A. Gut-man, J. S. Barnholtz-Sloan, J. E. V.
- 593 Vega, D. J. Brat, and L. A. Cooper. Predicting cancer outcomes from histology and genomics
- using convolutional networks. Proceedings of the National Academy of Sciences,
- 595 115(13):E2970–E2979, 2018.
- 596 22. S. Yousefi, F. Amrollahi, M. Amgad, C. Dong, J. E. Lewis, C. Song, D. A. Gutman, S. H.
- Halani, J. E. V. Vega, D. J. Brat, et al. Predicting clinical outcomes from large scale cancer
- 598 genomic profiles with deep survival models. Scientific reports, 7(1):1–11, 2017.
- 23. Y LeCun, Y Bengio. Convolutional networks for images, speech, and time series. The
 handbook of brain theory and neural networks 3361 (10), 1995
- 601 24. Adamson AS, Jarmul JA, Pignone MP. Screening for Melanoma in Men: a Cost-
- Effectiveness Analysis. J Gen Intern Med. 2020 Apr;35(4):1175-1181. doi: 10.1007/s11606-01905443-3. Epub 2019 Nov 8. PMID: 31705474; PMCID: PMC7174523.
- 604 25. Gordon LG, Brynes J, Baade PD, Neale RE, Whiteman DC, Youl PH, Aitken JF, Janda M.
- 605 Cost-Effectiveness Analysis of a Skin Awareness Intervention for Early Detection of Skin
- 606 Cancer Targeting Men Older Than 50 Years. Value Health. 2017 Apr;20(4):593-601. doi:
- 607 10.1016/j.jval.2016.12.017. Epub 2017 Feb 15. PMID: 28408001.
- 608 26. Tokez S, Alblas M, Nijsten T, Pardo LM, Wakkee M. Predicting keratinocyte carcinoma in
- 609 patients with actinic keratosis: development and internal validation of a multivariable risk-
- 610 prediction model. Br J Dermatol. 2020 Sep;183(3):495-502. doi: 10.1111/bjd.18810. Epub 2020
- 611 Feb 26. PMID: 31856292; PMCID: PMC7496285.
- 612 27. Olsen CM, Pandeya N, Thompson BS, Dusingize JC, Webb PM, Green AC, Neale RE,
- 613 Whiteman DC; QSkin Study. Risk Stratification for Melanoma: Models Derived and Validated
- 614 in a Purpose-Designed Prospective Cohort. J Natl Cancer Inst. 2018 Oct 1;110(10):1075-1083.
- 615 doi: 10.1093/jnci/djy023. PMID: 29538697.
- 616 28. Mar, V., Wolfe, R. and Kelly, J.W. (2011), Predicting melanoma risk for the Australian
- 617 population. Australasian Journal of Dermatology, 52: 109-116. <u>https://doi.org/10.1111/j.1440-</u> 618 $\underline{0960.2010.00727.x}$
- 619 29. Quéreux, Gaelle, et al. "Development of an Individual Score for Melanoma Risk." European
- Journal of Cancer Prevention, vol. 20, no. 3, 2011, pp. 217–24. JSTOR,
- https://www.jstor.org/stable/48504055. Accessed 23 Aug. 2023.
- 622 30. Whiteman DC, Thompson BS, Thrift AP, Hughes MC, Muranushi C, Neale RE, Green AC,
- Olsen CM; QSkin Study. A Model to Predict the Risk of Keratinocyte Carcinomas. J Invest
- 624 Dermatol. 2016 Jun;136(6):1247-1254. doi: 10.1016/j.jid.2016.02.008. Epub 2016 Feb 22.
- 625 PMID: 26908057.
- 626 31. Pothiawala S, Qureshi AA, Li Y, Han J. Obesity and the incidence of skin cancer in US
- 627 Caucasians. Cancer Causes Control. 2012 May;23(5):717-26. doi: 10.1007/s10552-012-9941-x.
- 628 Epub 2012 Mar 27. PMID: 22450736; PMCID: PMC3704194.

- 629 32. Zhou, D., Wu, J. & Luo, G. Body mass index and risk of non-melanoma skin cancer:
- 630 cumulative evidence from prospective studies. Sci Rep 6, 37691 (2016).
- 631 <u>https://doi.org/10.1038/srep37691</u>
- 632 33. Theodoros N. Sergentanis, Antonios G. Antoniadis, Helen J. Gogas, Constantine N.
- Antonopoulos, Hans-Olov Adami, Anders Ekbom, Eleni Th. Petridou. Obesity and risk of
- malignant melanoma: A meta-analysis of cohort and case-control studies, European Journal of
- 635 Cancer, Volume 49, Issue 3, 2013, Pages 642-657, <u>https://doi.org/10.1016/j.ejca.2012.08.028</u>.
- 636 34. George CD, Tokez S, Hollestein L, Pardo LM, Keurentjes AJ, Wakkee M, Nijsten T.
- 637 Longitudinal Assessment of the Prevalence of Actinic Keratosis and Extensive Risk Factor
- Evaluation: An Update from the Rotterdam Study. J Invest Dermatol. 2023 May 9:S0022-
- 639 202X(23)02056-0. doi: 10.1016/j.jid.2023.02.042. Epub ahead of print. PMID: 37169068.
- 640 35. Tokez, S., Alblas, M., Nijsten, T., Pardo, L.M. and Wakkee, M. (2020), Predicting
- 641 keratinocyte carcinoma in patients with actinic keratosis: development and internal validation of
- a multivariable risk-prediction model. Br J Dermatol, 183: 495-502.
- 643 https://doi.org/10.1111/bjd.18810
- 644 36. Bas H.M. van der Velden, Hugo J. Kuijf, Kenneth G.A. Gilhuijs, Max A. Viergever.
- Explainable artificial intelligence (XAI) in deep learning-based medical image analysis. Medical
- 646 Image Analysis. Volume 79, 2022, 102470, ISSN 1361-8415,
- 647 https://doi.org/10.1016/j.media.2022.102470.
- 648 37. Sajid Ali, Tamer Abuhmed, Shaker El-Sappagh, Khan Muhammad, Jose M. Alonso-Moral,
- 649 Roberto Confalonieri, Riccardo Guidotti, Javier Del Ser, Natalia Díaz-Rodríguez, Francisco
- 650 Herrera. Explainable Artificial Intelligence (XAI): What we know and what is left to attain
- Trustworthy Artificial Intelligence. Information Fusion. Volume 99, 2023, 101805, ISSN 1566-
- 652 2535, <u>https://doi.org/10.1016/j.inffus.2023.101805</u>
- 653 38. Markus Langer, Daniel Oster, Timo Speith, Holger Hermanns, Lena Kästner, Eva Schmidt,
- Andreas Sesing, Kevin Baum. What do we want from Explainable Artificial Intelligence (XAI)?
- 655 A stakeholder perspective on XAI and a conceptual model guiding interdisciplinary XAI
- research. Artificial Intelligence. Volume 296, 2021, 103473, ISSN 0004-3702,
- 657 https://doi.org/10.1016/j.artint.2021.103473
- 658 39. Erico Tjoa, Cuntai Guan. A Survey on Explainable Artificial Intelligence (XAI): Toward
- 659 Medical XAI. IEEE Transactions on Neural Networks and Learning Systems. Volume: 32, Issue: 11 November 2021, https://doi.org/10.1109/TNNU.S.2020.3027314
- 660 11, November 2021. https://doi.org/10.1109/TNNLS.2020.3027314
- 40. Fontanillas, P., Alipanahi, B., Furlotte, N.A. et al. Disease risk scores for skin cancers. Nat
- 662 Commun 12, 160 (2021). https://doi.org/10.1038/s41467-020-20246-5



Skin cancer on any location



Skin cancer on the face



Skin cancer on other regions other than the face



Higher risk







